2013
DOI: 10.1007/978-1-62703-484-5
|View full text |Cite
|
Sign up to set email alerts
|

Antiviral Methods and Protocols

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

0
3
0

Year Published

2013
2013
2024
2024

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 8 publications
(3 citation statements)
references
References 0 publications
0
3
0
Order By: Relevance
“…The analog, compound 6, had an improved antiviral activity as it inhibited MNV and the HuNoV GI.1 replicon with EC 50 values around 0.2 µM and 1.7 µM, respectively. In addition, compound 6 had a better antiviral effect against MNV and the HuNoV GI.1 replicon than 2CMC, which is currently used as the benchmark antiviral compound in norovirus research [13,14].…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…The analog, compound 6, had an improved antiviral activity as it inhibited MNV and the HuNoV GI.1 replicon with EC 50 values around 0.2 µM and 1.7 µM, respectively. In addition, compound 6 had a better antiviral effect against MNV and the HuNoV GI.1 replicon than 2CMC, which is currently used as the benchmark antiviral compound in norovirus research [13,14].…”
Section: Discussionmentioning
confidence: 99%
“…We determined that compound 6 acts at a post-entry step, most likely acting at the time viral genome replication starts. In fact, the presence of compound 6 is required at the same time points as that of the nucleoside analog 2CMC [14]. Hence, the first hypothesis was that compound 6 was also an RdRp targeting compound.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation